PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 1 | 3 | 158-164
Article title

Badania kliniczne a codzienna praktyka w terapii wysiękowego zwyrodnienia plamki związanego z wiekiem – doświadczenia własne

Content
Title variants
EN
Clinical research and everyday practice in wet form of age-related macular degeneration therapy – own experiences
Languages of publication
PL
Abstracts
EN
Neovascular age-related macular degeneration (AMD) is the leading cause of irreversible visual acuity loss in individuals with this pathology and also one of the most important causes of legal blindness in Poland and other developed countries. The intravitreal injection of ranibizumab continues to be the standard of care for the treatment of wet AMD. This article presents the cases of patients treated with ranibizumab and observed over the years, who demonstrated permanent positive effect of the drug on the functioning and morphology of the macula. Based on the clinical research and academic publications to date the most common treatment algorithms with ranibizumab, applied in everyday retinal practice, are described.
PL
Neowaskularyzacja w przebiegu zwyrodnienia plamki związanego z wiekiem (AMD, age-related macular degeneration) stanowi główną przyczynę utraty centralnego widzenia u chorych z tą patologią tylnego bieguna gałki ocznej i jednocześnie jedną z najważniejszych przyczyn prawnej ślepoty w Polsce i w innych krajach rozwiniętych. Terapia ranibizumabem pozostaje standardem w leczeniu wysiękowego AMD. W artykule przedstawiono przypadki chorych poddanych wieloletniej obserwacji i terapii ranibizumabem z zadowalającymi, trwałymi efektami czynnościowymi i morfologicznymi. Na podstawie badań klinicznych i piśmiennictwa opisano najczęstsze schematy terapii ranibizumabem obowiązujące w codziennej praktyce retinologicznej.
Discipline
Publisher

Journal
Year
Volume
1
Issue
3
Pages
158-164
Physical description
Contributors
  • Klinika Okulistyki WIM w Warszawie
References
  • 1. Brown DM, Kaiser PK, Michels M, et al; for the Anchor Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006; 355: 1432-1444.
  • 2. Boyer DS, Antoszyk AN, Awh CC. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114(2): 246-252.
  • 3. Tano Y, Ohji M. EXTEND-I: safety and efficacy of ranibizumab in Japanes patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010; 88: 309-316.
  • 4. Fung AE, Lalwani GA, Rosenfeld PJ. An optical coherence tomography – guided, variable dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
  • 5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009; 148(1): 43-58.
  • 6. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol 2013; 97: 1161-1167.
  • 7. Martin DF, Maguire MG, et al; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
  • 8. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007; 85: 486-494.
  • 9. Boyer DS, Heier JS, Brown DM, et al. A phase III b study to evaluate the safety of ranibizumab in subject with neovascular agerelated macular degeneration. Ophthalmology 2009; 116(9): 1731-1739.
  • 10. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study. Ophthalmology 2011; 118(4): 663-671.
  • 11. Pushpoth S, Sykakis E, Merchant K, et al. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96: 1469-1473.
  • 12. Mitchell P, Bressler N, Doan QV, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS 2014; 30: 9(6): e101072. doi: 10.1371/journal.pone.0101072. eCollection 2014.
  • 13. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014 Jul 7. pii: bjophthalmol-2014-305252. doi: 10.1136/bjophthalmol-2014-305252.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-08ed9238-69e8-4089-8e0c-b0c1e4e33b13
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.